ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Clinical characteristics and status of treatment of small-cell carcinoma of the ovary, hypercalcemic type in the Chinese population: a meta-analysis.Journal of gynecologic oncology · 2024Pooled it
- A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort.Cancer communications (London, England) · 2025Trial
- Pregnancy-Associated Small Cell Carcinoma of the Ovary, Hypercalcaemic Type Initially Misdiagnosed as Granulosa Cell Tumour: Diagnostic Pitfalls, Treatment Challenges, and Molecular Confirmation by Next-Generation Sequencing.Cancer reports (Hoboken, N.J.) · 2026Article
- DeepICER: A deep learning framework for predicting compound-induced gene expression profiles.Acta pharmaceutica Sinica. B · 2026Article
- An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where.Virchows Archiv : an international journal of pathology · 2026Review
- SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.NPJ precision oncology · 2026Article
- Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.Cancer research · 2025Article
- Single-cell RNA sequencing reveals the intra-tumoral heterogeneity and immune microenvironment of small cell carcinoma of the ovary, hypercalcemic type.Journal of ovarian research · 2025Article
- Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer.Science advances · 2025Article
- Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.iScience · 2025Article
- mTOR Inhibitor Everolimus Modulates Tumor Growth in Small-Cell Carcinoma of the Ovary, Hypercalcemic Type and Augments the Drug Sensitivity of Cancer Cells to Cisplatin.Biomedicines · 2024Article
- Review
- Chromatin remodellers as therapeutic targets.Nature reviews. Drug discovery · 2024Review
- EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.International journal of molecular sciences · 2024Article
- Article
- Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss.Nature communications · 2023Article
- Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy.International journal of molecular sciences · 2022Review
- GermlineJCO precision oncology · 2022Article
- Network controllability solutions for computational drug repurposing using genetic algorithms.Scientific reports · 2022Article
- Construction and validation of a prognostic model for hepatocellular carcinoma: Inflammatory ferroptosis and mitochondrial metabolism indicate a poor prognosis.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 3 countries.
Jessica D Lang *Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
William P D Hendricks *Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Krystal A OrlandoDepartment of Pathology and Laboratory Medicine, Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Hongwei YinDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Jeffrey KieferDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Pilar RamosDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Ritin SharmaCollaborative Center for Translational Mass Spectrometry, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Patrick PirrotteCollaborative Center for Translational Mass Spectrometry, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Elizabeth A RaupachDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Chris SeredukDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Nanyun TangDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Winnie S LiangDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Megan WashingtonDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Salvatore J FacistaDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Victoria L ZismannDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Emily M CousinsDepartment of Cell Biology and Physiology, Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Michael B MajorDepartment of Cell Biology and Physiology, Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Yemin WangDepartment of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Anthony N KarnezisDepartment of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Aleksandar SekulicDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona.
Ralf HassDepartment of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany.
Barbara C VanderhydenDepartment of Cellular and Molecular Medicine, University of Ottawa, and Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Praveen NairMolecular Response, San Diego, California.
Bernard E WeissmanDepartment of Pathology and Laboratory Medicine, Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
David G HuntsmanDepartment of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Jeffrey M TrentDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, Arizona. jtrent@tgen.org.
Translational Genomics Research Institute · USUniversity of North Carolina at Chapel Hill · USBC Cancer Agency · CAIntermolecular (United States) · USMedizinische Hochschule Hannover · DEOntario Institute for Cancer Research · CA
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3MTRAINING IN RESPIRATORY AND ENVIRONMENTAL MEDICINET32HL007106 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES, DOERSCHUK, CLAIRE M · 1985 to 2021
$7.3MThe Tumor Suppressor Role of SMARCA4 in SCCOHTR01CA195670 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUNTSMAN, DAVID, TRENT, JEFFREY M. · 2015 to 2019
$3.7MNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA195670NHLBI NIH HHS T32 HL007106
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsCarcinoma, Small CellCell Line, TumorComputational BiologyDisease Models, AnimalFemaleHumansImidazolesMiceOvarian NeoplasmsProtein Interaction MappingProtein Interaction MapsProtein Kinase InhibitorsPyridazinesReceptor Protein-Tyrosine KinasesAntineoplastic AgentsImidazolesponatinibProtein Kinase InhibitorsPyridazinesReceptor Protein-Tyrosine KinasesRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.